Home › Research › Treatments
The effects of donepezil in Alzheimer's disease - results from a multinational trial
Burns A, Rossor M, Hecker J, Gauthier S, Petit H, Möller HJ, Rogers SL, Friedhoff LT.. Dementia and geriatric cognitive disorders, 1999-05-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Donepezil has been shown to be well tolerated and to improve cognition and global function in patients with mild to moderately severe Alzheimer's disease (AD). The current trial was undertaken to investigate further the efficacy and safety of donepezil, in a multinational setting, in patients with mild to moderately severe AD. This 30-week, placebo-controlled, parallel-group study consisted of a 24-week, double-blind treatment phase followed by a 6-week, single-blind, placebo washout. Eight hundred and eighteen patients with mild to moderately severe AD were randomly allocated to treatment with single, daily doses of 5 or 10 mg donepezil, or placebo. The two primary efficacy measures were: a cognitive performance test, the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) and a global evaluation, the Clinician's Interview-Based Impression of Change with caregiver input (CIBIC plus). Secondary outcome measures included the Sum of the Boxes of the Clinical Dementia Rating Scale (CDR-SB), a modified Interview for Deterioration in Daily living activities in Dementia (IDDD) and a patient rated quality of life assessment. Statistically significant improvements in cognitive and global function were observed, as evaluated by ADAS-cog and CIBIC plus, respectively, in both the 5 and 10 mg/day donepezil groups, compared with placebo. Treatment-associated changes were also observed in functional skills, as shown by improved scores on the CDR-SB and the complex-tasks component of the IDDD. A dose-response effect was evident, with the 10 mg/day donepezil group demonstrating greater benefits in all outcome measures than the 5 mg/day group. Donepezil was well tolerated by this patient population and did not produce any clinically significant laboratory test abnormalities. The results of this study confirm that donepezil is effective and well tolerated in treating the symptoms of mild to moderately severe AD.
What this study adds
Evidence grade: Low
This is a trial. In this 30-week randomized trial, both 5 and 10 mg/day of donepezil produced statistically significant improvements in cognitive and global function compared with placebo in mild to moderately severe Alzheimer's disease. The study confirms donepezil is effective and well tolerated for symptoms, not that it cures or prevents the disease.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Burns, A., Rossor, M., Hecker, J., Gauthier, S., Petit, H., Möller, H. J., et al. (1999). The effects of donepezil in Alzheimer's disease - results from a multinational trial. Dementia and geriatric cognitive disorders. https://doi.org/10.1159/000017126
Vancouver
Burns A, Rossor M, Hecker J, Gauthier S, Petit H, Möller HJ, et al. The effects of donepezil in Alzheimer's disease - results from a multinational trial. Dementia and geriatric cognitive disorders. 1999. doi:10.1159/000017126. PMID: 10325453.
BibTeX
@article{burns1999-10325453,
author = {Burns, A. and Rossor, M. and Hecker, J. and Gauthier, S. and Petit, H. and Möller, H. J. and Rogers, S. L. and Friedhoff, L. T.},
title = {{The effects of donepezil in Alzheimer's disease - results from a multinational trial}},
journal = {Dementia and geriatric cognitive disorders},
year = {1999},
doi = {10.1159/000017126},
pmid = {10325453},
url = {https://doi.org/10.1159/000017126}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 8 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- Statistically significant improvements in cognitive and global function were observed, as evaluated by ADAS-cog and CIBIC plus, respectively, in both the 5 and 10 mg/day donepezil groups, compared with placebo.
- Donepezil was well tolerated by this patient population and did not produce any clinically significant laboratory test abnormalities.
- The results of this study confirm that donepezil is effective and well tolerated in treating the symptoms of mild to moderately severe AD.
Why it matters
In this 30-week randomized trial, both 5 and 10 mg/day of donepezil produced statistically significant improvements in cognitive and global function compared with placebo in mild to moderately severe Alzheimer's disease. The study confirms donepezil is effective and well tolerated for symptoms, not that it cures or prevents the disease.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 62/100
Published in a peer-reviewed journal, and it is a randomized controlled trial. Scored zero for sample size and effect reported because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Dementia and geriatric cognitive disorders) |
| Journal's citation record | 1 / 4 | Dementia and Geriatric Cognitive Disorders: journal h-index 149 (OpenAlex, 2026-10-29) |
| Study design | 11 / 12 | A randomized controlled trial (from PubMed type “Randomized Controlled Trial”) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 1999 — older than 20 years, still counted |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (pubmed indexes it as a clinical or observational study) |
| Randomized / blinded | 2 / 2 | Randomized and blinded or placebo-controlled (as stated in the record) |
| Times cited | 6 / 7 | Cited 584 times (OpenAlex, 2026-10-10) |
| Citations per year | 4 / 5 | 20.1 citations a year over 29 year(s) since 1999 |
| Impact for its field and year | 5 / 6 | Cited 27.9× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 3 / 6 | Cited by 29 other studies in this library |
| Still being cited | 2 / 4 | Cited 23 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Lawrence T. Friedhoff: h-index 19 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | McGill University: institution h-index 1,373 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 8 institution(s) in 6 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 10325453) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 62 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1159/000017126
- PubMed: 10325453
- Original source →
- Free full text: Dementia and Geriatric Cognitive Disorders →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
29 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Treatments from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.